Login
Anixa Biosciences Inc logo

Anixa Biosciences Inc

anixa.com

Anixa Biosciences (NASDAQ: ANIX) is a clinical-stage biopharmaceutical company developing prophylactic cancer vaccines and cancer-focused therapeutics. The company generates no product revenue and funds operations through equity issuances, having raised approximately $2,378,000 net of expenses via an at-the-market common stock offering during the fiscal year ended October 31, 2025. As of October 31, 2025, Anixa had up to $100 million remaining capacity under its at-the-market equity program. The company's business model conserves capital by collaborating with third parties to develop its technologies rather than building internal manufacturing or commercial infrastructure. Target indications include ovarian cancer and lung cancer, two areas the company identifies as having significant unmet medical need. Anixa is led by Dr. Amit Kumar, Chairman and Chief Executive Officer, and Michael J. Catelani, President, Chief Operating Officer, and Chief Financial Officer. The fiscal year ends October 31.

Products & Services

Prophylactic cancer vaccines targeting ovarian cancer and lung cancer therapeutics. Clinical-stage pipeline with no approved or commercialized products as of the 10-K filed January 12, 2026.

Revenue Model

No product revenue. Operations are funded through at-the-market equity offerings of common stock. The company raised approximately $2,378,000 net of expenses through 772,001 shares sold in the fiscal year ended October 31, 2025.

Customers & Markets

No commercial customers. End markets are oncology and preventive medicine, specifically targeting women age 60 and over at elevated ovarian cancer risk and lung cancer patients. The company cites an estimated 21,000 new U.S. ovarian cancer diagnoses and approximately 42 million U.S. women age 60 and over as the addressable prevention population (per American Cancer Society statistics cited in the FY2025 10-K).

Geographic Exposure

U.S.-focused based on filing and clinical activity disclosures. No international revenue or geographic segment data disclosed in the excerpts.

Financial Snapshot

Revenue
TTM
$0.00
Gross Margin
Last 4 Quarters
N/A
Net Income
TTM
-$10.03M
Current Assets
2026 Q2
Current Liabilities
2026 Q2
Current Ratio
2026 Q2
978.81%
Total Assets
2026 Q2
Total Liabilities
2026 Q2
Book Value
2026 Q2
$13.22M
Cash
2026 Q2
P/E
Last 4 Quarters
N/A
Free Cash Flow
Last 4 Quarters
N/A

Stock Price

Loading...
Market Cap: $104.11 Million

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support